Top Page
NeOnc Technologies Holdings, Inc.
(NASDAQ:NTHI)
NeOnc Technologies Holdings, Inc. (NTHI) vs. SPDR S&P 500 ETF (SPY)
NeOnc Technologies Holdings, Inc. Business Overview & Revenue Model
NeOnc Technologies Holdings, Inc. Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 59.99K | 83.00K | 70.46K | 20.00K | 0.00 |
| Gross Profit | 41.68K | 83.00K | 70.46K | 20.00K | 0.00 |
| EBITDA | -53.23M | -9.10M | -12.20M | -2.85M | -3.26M |
| Net Income | -54.55M | -11.90M | -14.92M | -3.05M | -3.38M |
Balance Sheet | |||||
| Total Assets | 4.08M | 3.42M | 1.27M | 728.68K | 32.49K |
| Cash, Cash Equivalents and Short-Term Investments | 1.51M | 64.89K | 31.86K | 633.30K | 25.03K |
| Total Debt | 378.74K | 24.72K | 6.61M | 50.00K | 1.15M |
| Total Liabilities | 15.90M | 8.92M | 15.25M | 2.30M | 2.65M |
| Stockholders Equity | -11.81M | -5.50M | -13.99M | -1.58M | -2.62M |
Cash Flow | |||||
| Free Cash Flow | -17.73M | -4.21M | -1.88M | -881.74K | -396.69K |
| Operating Cash Flow | -17.73M | -4.21M | -1.88M | -881.74K | -396.69K |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 17.91M | 4.25M | 1.28M | 1.49M | 250.00K |
NeOnc Technologies Holdings, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $38.47M | -0.65 | -67.47% | ― | ― | 9.63% | |
49 Neutral | $213.99M | -5.06 | ― | ― | ― | ― | |
46 Neutral | $3.87M | -0.38 | -377.44% | ― | 8.52% | 79.51% | |
45 Neutral | $5.52M | -0.36 | ― | ― | ― | 87.42% | |
41 Neutral | $14.83M | -0.13 | -356.99% | ― | ― | 54.62% |
NeOnc Technologies Holdings, Inc. Corporate Events
On January 29, 2026, NeOnc Technologies Holdings, Inc. entered into a Securities Purchase Agreement to issue up to 2,222,222 shares of common stock at $7.20 per share and accompanying five-year warrants for an equal number of shares at an exercise price of $9.00. At the initial closing, the company sold 1,388,888 shares and warrants to a single institutional investor for $10 million, with additional closings expected, and plans to use the net proceeds to repay indebtedness and fund working capital. The securities were issued in a private placement exempt from Securities Act registration, and the company committed to file a resale registration statement for the shares and warrant shares within ten days of the initial closing, underscoring a strategy to strengthen its balance sheet and provide liquidity to the investor.
The most recent analyst rating on (NTHI) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on NeOnc Technologies Holdings, Inc. stock, see the NTHI Stock Forecast page.
On December 15, 2025, NeOnc Technologies Holdings, Inc. reported updated results from its clinical trials evaluating intranasal NEO100 for recurrent WHO Grade III/IV IDH1-mutant astrocytoma patients. Results showed significant advancements, as 24% of trial participants achieved radiographic remission, substantially outperforming typical rates of salvage therapies. Additionally, 44% of patients achieved progression-free survival at six months, and 36% demonstrated durable survival for at least 18 months. These findings point to NEO100’s potential as a transformative CNS-penetrant metabolic therapy with significant survival benefits in heavily pretreated populations, challenging historically palliative approaches. No toxicity concerns were observed, further backing its promise to improve treatment outcomes for CNS cancer patients.
On December 1, 2025, NeOnc Technologies Holdings, Inc. announced a Securities Purchase Agreement with investor Saad Naja for the sale of 111,732 shares of common stock at $8.95 per share, raising approximately $1 million to be used for working capital. Additionally, NeOnc revealed preclinical findings from a collaboration with the University of Southern California, showing that ultrasound enhances the effectiveness of NEO100 in treating brain tumors, potentially expanding its clinical and commercial opportunities.
NeOnc Technologies Holdings, Inc. announced significant corporate and clinical developments for Q3 2025. The company reported progress in its NEO100 and NEO212 clinical trials, with NEO100 showing promising Phase 2a results for recurrent brain cancer. Additionally, NeOnc secured a $50 million partnership with Quazar Investment and received $2.5 million in NIH funding, enhancing its financial and strategic positioning. The appointment of key leadership figures and inclusion in the Russell Microcap Index further bolster its market visibility and institutional investor exposure. These developments indicate a strengthened foundation for NeOnc’s long-term growth and innovation in CNS oncology.
On November 12, 2025, NeOnc Technologies Holdings, Inc. announced updated clinical results from its Phase 1/2a and compassionate care studies involving 24 patients with recurrent Grade III/IV IDH1-mutant astrocytoma treated with NEO100. The results showed significant radiographic response in 21% of patients and a 44% six-month progression-free survival rate, surpassing historical benchmarks. Additionally, 33% of patients demonstrated long-term survival of 18 months or more, with no significant toxicity reported. These findings suggest NEO100 could represent a paradigm shift in treating recurrent IDH1-mutant gliomas, potentially offering a new standard of care.
On November 7, 2025, NeOnc Technologies Holdings, Inc. announced an investor conference call scheduled for November 12, 2025, to present data updates from its ongoing Phase 1/2a NEO100-1 clinical trial and compassionate use program. The discussion will focus on MRI-based radiographic response data, progression-free survival, and overall survival trends for patients with recurrent high-grade malignant glioma, potentially impacting the company’s operations and industry positioning.
On October 31, 2025, NeOnc Technologies Holdings, Inc. announced significant leadership changes with Dr. Thomas Chen resigning as CEO to focus on his roles as Chief Medical Officer and Chief Scientific Officer. Amir Heshmatpour was appointed as the new CEO, effective immediately, while continuing his roles as President and Executive Chairman. This leadership transition is part of NeOnc’s strategy to advance its clinical trials and capitalize on Heshmatpour’s expertise in corporate strategy and business development, aiming to drive the company’s next phase of growth and innovation in CNS cancer therapies.
On October 28, 2025, NeOnc Technologies Holdings, Inc. announced that His Highness Sheikh Nahyan bin Zayed Al Nahyan will assume the role of Executive Chairman of NuroMENA Holdings Ltd., its Middle East subsidiary. This strategic move is expected to significantly impact the company’s operations and position the UAE at the forefront of brain cancer treatment innovation, leveraging sovereign resources to address global health challenges.